Nanologica was founded in 2004 and is a nanotechnology company developing nanoporous silica particles for applications within life science. Nanologica is world leading in controlling shape, porosity and surface characteristics of silica particles. This competency is applied in two business areas – drug development and chromatography, a separation technique used in drug development and drug production. The Company’s mission is to contribute to providing better and cheaper treatments for patients worldwide through the technology platform NLAB Silica™. The Company’s share (NICA) is traded on Spotlight Stock Market.